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Neurocutaneous melanosis (NCM) is a rare congenital disorder characterized by the association of large and/or
multiple congenital melanocytic nevi (CMN) of the skin with melanocytic lesions of the leptomeninges, including
melanocytosis. Leptomeningeal melanocytosis carries a poor prognosis once neurological symptoms develop.
Despite surgery, which is often not radical, few other treatment options exist. Recently, it was demonstrated that
early embryonic, post-zygotic somatic mutations in the NRAS gene are implicated in the pathogenesis of NCM.
In this report, we present a 13-year-old boy with NCM and progressive symptomatic leptomeningeal melanocytosis.
A somatic NRASQ61K mutation was present in both CMN as well as the melanocytosis. Despite repeated surgery,
the patient showed clinical progression. Therefore, treatment with MEK162, a MEK inhibitor, was started on compassionate
use base. The patient died only five days later, i.e. too early to expect a clinical effect of MEK162 therapy. We therefore
studied the effect of MEK162 at the protein level in the leptomeningeal tumor by immunohistochemical and Western
Blot analyses using Ki67 and pERK antibodies. We observed lower MIB-1 expression and lower pERK expression in the
post-treatment samples compared to pre-treatment, suggesting a potential effect of MEK inhibiting therapy. Further
studies are needed to determine whether MEK inhibitors can effectively target NRAS-mutated symptomatic NCM, a rare
but potentially fatal disease.
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Neurocutaneous melanosis (NCM) is a rare congenital
disorder first described by Rokitansky in 1861, in which
affected patients have an increased number of melano-
cytes in the leptomeninges of the central nervous system
(CNS) and the skin [1,2]. The diagnostic criteria for
NCM, originally proposed by Fox [3] and revised by
Kadonaga and Frieden [1] include large or multiple con-
genital melanocytic nevi (CMN) of the skin associated
with leptomeningeal melanocytosis or (primary) lepto-
meningeal melanoma. The pathogenesis of NCM has
not been fully elucidated but it is thought to represent a* Correspondence: h.kusters@cwz.nl
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melanocytes.
Leptomeningeal melanocytosis consists of a diffuse prolif-
eration of histologically benign appearing melanocytes in
the leptomeninges, without evident invasion of the CNS
[4]. Patients can develop neurological symptoms due to im-
paired CSF drainage resulting in increased intracranial
pressure and/or due to mass effect on the brain or spinal
cord. Even in the absence of malignant progression, lepto-
meningeal melanocytosis carries a poor prognosis once
neurological symptoms develop [1,5].
So far, surgical resection of the leptomeningeal tumor
is the treatment of choice, but complete resection is
often impossible. In addition, the value of chemotherapy
and radiotherapy is not clear [1]. Recently, a few studies
have demonstrated that early embryonic, post-zygoticMed Central Ltd. This is an Open Access article distributed under the terms of
tp://creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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the development of NCM [6,7].
In this case report, we present a 13-year-old boy with
NRAS-mutated leptomeningeal melanocytosis in the con-
text of NCM. Despite repeated surgery, the patient showed
clinical progression and treatment with MEK162, a MEK
inhibitor, was started on compassionate use. Unfortunately,
the patient died only five days after start of this treatment,
i.e. too early to expect a clear clinical effect. We therefore
proceeded with investigating the potential effect of
MEK162 at the protein level by immunohistochemical
and Western Blot analyses using Ki67 and pERK anti-
bodies. We observed lower MIB-1 expression and
lower pERK expression in the post-treatment melano-
cytosis samples compared to the pre-treatment sample,
suggesting a potential effect of MEK inhibiting therapy.
Case presentation
Patient history
A 13-year-old boy was admitted to the outpatient clinic
of pediatric neurology with progressive neurological
symptoms. Since birth, he had multiple large melano-
cytic nevi of the skin (trunk, legs, arms, face) for which
multiple resections were performed in the past. As aFigure 1 Brain and spinal MRI images. A. MRI of the brain showed an e
through the foramen magnum, and an enlarged subarachnoid cistern ante
the floor of the third ventricle. The brain stem appeared to be compressed
weighted image with contrast. B. Spinal MRI showed a widened spinal can
multiple cysts with extensive leptomeningeal and dural contrast enhancem
contrast. C and D. MRI of the brain and spinal cord, a few months after sur
spinal cord with (further) compression of these structures and hydrocephalchild, his developmental milestones for speech and fine
motor skills were slightly delayed. Now, he presented
with vertigo, headache, nausea, vomiting and pain in
his legs. Neurological examination revealed bilateral
papilloedema, slurred speech, dysmetria and dysdiado-
chokinesis of both arms, and an unsteady gait due to
cerebellar ataxia plus mild pyramidal tract and sensory
involvement. Knee and ankle jerk reflexes were clearly
increased, but plantar responses were normal. MRI of
the brain showed enhanced signal intensity of the uncus,
an enlarged fourth ventricle in contact with a retrocere-
bellar cyst extending through the foramen magnum, and
an enlarged subarachnoid cistern anterior to the brain-
stem, extending from the medulla oblongata towards the
floor of the third ventricle. The brain stem appeared to
be compressed or atrophied due to the combined pres-
sure from these cysts (Figure 1A). Spinal MRI showed a
widened spinal canal and a distorted and atrophic spinal
cord, due to the presence of multiple cysts with exten-
sive leptomeningeal and dural contrast enhancement
without the presence of solid masses (Figure 1B). Based
on the history of large congenital melanocytic nevi
(CMN) and the neuroradiological findings, a diagnosis
of NCM was made.nlarged fourth ventricle in contact with a retrocerebellar cyst extending
rior to the brainstem, extending from the medulla oblongata towards
or atrophied due to the combined pressure from these cysts. T1
al and a distorted and atrophic spinal cord, due to the presence of
ent without the presence of solid masses. T1 weighted image with
gery, showed progressive leptomeningeal lesions of the brain and
us (C with, D without contrast).
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tain material for histology, a suboccipital decompression
was performed with drainage of the cerebellar cyst.
Intra-operatively, the floor of the fourth ventricle was
covered with small cystic lesions (Figure 2A), the arach-
noid around the spinal cord was thickened and disco-
lored (Figure 2B), and the cyst wall covered all cranial
nerves and arteries lateral to the brain stem, inhibiting
cerebrospinal fluid flow (Figure 2C).
Histopathological examination indeed showed lepto-
meningeal melanocytosis and thus confirmed the clinical
diagnosis of NCM. Mutation analysis revealed a mutation
in exon 3 at codon 61 of NRAS (c.1818C >A (p.(Gln61Lys)
alias “Q61K”). On revision, the previously removed con-
genital nevi from both legs, left arm, right shoulder and
right eyebrow were melanocytic nevi without signs of ma-
lignancy. NRAS mutation analysis of one of them showed
an identical NRAS mutation as in the leptomeningeal
melanocytosis. The NRAS mutation was absent in normal
skin, thereby excluding an NRAS germ-line mutation. After
surgery, the patient initially improved. In the following
months, however, neurological symptoms increased and
repeated imaging showed progressive leptomeningeal le-
sions around the brain and spinal cord with (further) com-
pression of these structures and hydrocephalus (Figure
1C-D). In an attempt to relieve some of the symptoms, a
ventriculo-peritoneal shunt was placed in the right lateral
ventricle. However, the fourth ventricle enlarged again due
to aquaduct stenosis. Hence, aquaduct stenting was per-
formed. Unfortunately, this could not prevent further
deterioration. At that time there were no neurosurgical
options left and we refrained from radiotherapy since it
was unlikely that irradiation would provide rapid clin-
ical benefit.
In view of the previously described beneficial effect of
MEK162 in NRAS-mutated metastatic melanoma, and
knowing that our patient carried an activating NRAS
mutation in his leptomeningeal melanocytosis lesion, we
considered treatment of our patient with MEK162. NovartisFigure 2 Intra-operative photographs of the medulla spinalis and the
covered with small cystic lesions (fourth ventricle, cervical medulla on top)
of the arachnoid around the spinal cord (image of part proximal of C1). C.
lateral to the brain stem, inhibiting normal flow of cerebrospinal fluid (acceagreed to supply MEK162 on compassionate use base, and
after screening for eligibility and parental consent treatment
with MEK162 45 mg BID was started.
In the following days however, the patient was re-
admitted to the hospital because of further deterioration
with progressive general weakness and stridor. He had
papules on the chest, consistent with mild skin toxicity
due to MEK162. Cerebral MRI confirmed disease pro-
gression. Five days after starting MEK162 treatment, the
boy died due to central neurogenic respiratory failure.
The parents gave permission to perform autopsy.
Autopsy findings and histology
At autopsy, multiple large CMN were seen on the skin,
mainly on the trunk, some with scars because of previous
surgical removal. At the base of the brain (Figure 3A),
around the cerebellar hemispheres and the brainstem, the
leptomeninges were greyish and thickened, embedding
blood vessels and cranial nerves, and obstructing the
cerebellar cisterna and foramina. This prominent lepto-
meningeal thickening extended along the entire spinal
cord resulting in a thick, plaque-like tumor compressing
especially the cervical region of the spinal cord (Figure 3C).
Some nodular thickening of leptomeninges around spinal
nerve roots was present, while nerve roots from the cauda
equina were completely embedded in leptomeningeal
tumor. At cut surface of the brain, black discoloration was
seen of the amygdala and focally in the right basal cortex.
Microscopically, a leptomeningeal proliferation con-
sisting of melanocytic cells was seen (Figure 3B,D-E),
confirmed by staining for S100, Melan-A and HMB-45.
The melanocytic cells were ovoid and monotonous, with
little cytonuclear atypia (Figure 3E) and occasionally some
cytoplasmic melanin pigment. Necrosis was absent and mi-
totic activity was low. Extension of melanocytic cells in the
perivascular Virchow Robin spaces of the brain (Figure 3B)
and spinal cord was present, without frank invasion of the
CNS parenchyma. Compression of the brain stem by the
diffuse leptomeningeal melanocytosis, causing respiratoryspinal cord. A. Intra-operatively, the floor of the fourth ventricle was
. B. Intra-operative photograph showing thickening and discoloration
Intra-operatively, the cyst wall covered all cranial nerves and arteries
ssory nerve and arteries lateral to the brain stem).
Figure 3 Macro- and microscopy of the brain and the spinal cord obtained at autopsy. A. The leptomeninges at the base of the brain were greyish
and thickened, embedding blood vessels and cranial nerves. B. Microscopically, a leptomeningeal proliferation consisting of melanocytic cells was seen
with extension of these cells in the perivascular (Virchow-Robin) spaces of the brain, without frank invasion of the CNS parenchyma. C. The spinal cord
was surrounded by a thickened brown-greyish tumorous proliferation. This prominent leptomeningeal thickening extended along the entire spinal cord,
resulting in a thick, plaque-like tumor compressing especially the cervical region of the spinal cord. D. Microscopy of a transverse section of the spinal cord.
E. The melanocytic cells were ovoid and monotonous, with little cytonuclear atypia. Necrosis was absent and mitotic activity was low.
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cause of death. Histological examination of the nevi at
autopsy and revision of previously removed CMN, demon-
strated compound melanocytic nevi with congenital fea-
tures, without signs of malignancy.
Immunohistochemistry
To study whether MEK162 had sorted an effect on the
leptomeningeal melanocytosis after 5 days of treatment,
tumor tissue removed at operation before MEK162 treat-
ment and tumor tissue at autopsy, was stained with the
antibodies Ki67 (MIB-1) and pERK. Details on staining
methods are presented in the Additional file 1. MIB-1
staining was performed on the pretreatment FFPE-
sample and several postmortem FFPE-specimens of mel-
anocytosis from different anatomic regions of the CNS
(including cerebrum (parieto-occipital and frontobasal
region), cerebellum, brainstem, different levels of spinal
cord). The percentage of MIB-1-positive nuclei was
semi-quantitatively assessed in hotspot regions at ×
400 magnification counting at least 600 to 1000 cells.
The pre-treatment sample contained several hotspots
showing a MIB-1 Labelings Index (LI) of 5% (Figure 4A
and B). In contrast, the melanocytosis samples after
MEK162 treatment all showed lower MIB-1 expression
with a MIB-1 LI of <1%, suggesting little tumor hetero-
geneity throughout the tumor as far as proliferative ac-
tivity is concerned (Figure 4C and D).Furthermore, 75% of tumor cells in the pre-treatment
sample were positive in the pERK stain versus 25%
of tumor cells in the post-treatment sample (Figure
4E, pre-treatment, and Figure 4F pERK staining post-
treatment).Mutation analysis
An identical mutation in exon 3 at codon 61 of NRAS
(c.1818C > A (p.(Gln61Lys) alias “Q61K”) was present in
the melanocytosis tissue removed at surgery and in one
of the congenital nevi removed in the past, while normal
skin did not reveal an NRAS mutation, thereby excluding
an NRAS germ-line mutation. We also tested the mela-
nocytosis sample for mutations in codon 600 of BRAF
and for oncogenic mutations in codon 209 of the GNAQ
and GNA11 genes, as the latter are present in adult
cases of primary leptomeningeal melanocytic neoplasms
[8,9]. Mutations in these genes were absent.Western Blotting
Unfortunately, the brain specimen before MEK162 treat-
ment was insufficient for Western Blot analysis. In the
brain sample that was obtained by autopsy the Western
Blot showed presence of total ERK, but not of pERK,
which is in line with the immunohistochemical staining
results. See Figure 4G and 4H.
Figure 4 Pre- and posttreatment MIB-1 and pERK stains and Western Blot analysis. A and B. MIB-1 expression in the leptomeningeal melanocytosis
sample before MEK162 treatment, in two hotspot regions (5% MIB-1-positive cells). C and D. The melanocytosis samples after MEK162 treatment showed
lower MIB-1 expression than pre-treatment (<1% MIB-1-positive cells (arrows); compare with Figure 4A and B. C temporobasal brain and D frontobasal
brain. E. pERK protein expression in the leptomeningeal melanocytosis before MEK162 treatment. Endothelial cells serve as a positive internal control
(arrow). F. pERK protein expression after MEK162 treatment showing lower pERK expression than pre-treatment (compare with 4E). G and H. Western Blots
showing expression of pERK (G) and total ERK (H) in the brain sample after MEK162 treatment (lane 4), along with Rh-18 and Granta-519 as positive and
negative controls in lanes 2 and 3, respectively. In the brain sample, pERK cannot be detected after MEK162 treatment (G), whereas total ERK is present (H),
as indicated by the long arrows. Short arrows indicate GAPDH expression.
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This case report describes a 13-year-old boy, known
since birth with multiple large CMN, who developed pro-
gressive neurological symptoms due to leptomeningeal mel-
anocytosis. The association of large and/or multiple CMN
of the skin with melanocytic lesions of the CNS is known
as NCM [1]. The CNS manifestations in NCM include
leptomeningeal melanocytosis or melanoma, but alsomelanotic abnormalities with intraparenchymal deposits of
melanin as well as associations with CNS malformations
have been reported [1,10-12].
Leptomeningeal melanocytosis has a poor prognosis once
neurological symptoms develop and treatment mostly in-
cludes surgical interventions to reduce intracranial pres-
sure. The efficacy of irradiation and chemotherapy for this
disorder is unclear [1].
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zygotic somatic mutations in the NRAS gene are implicated
in the development of NCM and childhood melanoma of
the CNS [6,7,9]. Thus far, all primary childhood melanomas
of the CNS and leptomeningeal melanocytosis were found
to harbor somatic NRAS mutations: in the 6 cases re-
ported in literature, including the present case, a codon 61
mutation in NRAS was demonstrated (1 case Q61L, 3
cases Q61R, 2 cases Q61K) [6,7,9]. It can be hypothesized
that early during embryogenesis a melanocyte precursor
acquires a somatic NRAS mutation resulting in a ‘mosaic’
pattern of melanocytes that colonize the skin and
leptomeninges. This could explain the presence of an
identical somatic NRAS mutation in the CMN as
well as in the leptomeningeal melanocytosis in this
patient.
Recently, a non-randomized phase-2 study has demon-
strated that MEK162 shows activity in NRAS-mutated
melanoma [13]. In addition, we previously reported on a
mouse model in which embryonic induction of onco-
genic NRAS mutation led to NCM-like disease in mice
with development of primary CNS melanoma [6]. In that
study, we were able to demonstrate that cells derived
from the primary CNS melanomas in the mice displayed
constitutive ERK activity and that those cells were sensitive
to the MAP–ERK kinase (MEK) inhibitors PD184352,
U0126, and AZD6244. Such information led us to start
MEK162 treatment on compassionate use base in our pa-
tient. Unfortunately, the patient passed away only five days
later and we were not able to assess the clinical effect of
MEK162 treatment. However, immunohistochemical ana-
lysis revealed that after MEK162 treatment proliferation as
well as pERK expression was lower in the leptomeningeal
melanocytosis as compared to the pre-treatment situation.
Of course these findings in a single patient should be inter-
preted with caution. Still, our findings are in line with those
of another recent case report, reporting effect of vemurafe-
nib in a patient with diffuse leptomeningeal melanoma me-
tastasis carrying an activating BRAF mutation [14].
In the largest phase 2 study of MEK162 in melanoma pa-
tients so far, MEK162 was well tolerated overall [13]. The
most common toxicities were skin- and gastrointestinal-
related and fluid retention. These toxicities were generally
mild and well manageable. More severe adverse events
were uncommon; the most common grade 3–4 adverse
event was an asymptomatic rise in creatine phosphokinase
[13]. So far, no increased risk of paradoxical tumor develop-
ment has been observed, as has been described with BRAF
inhibitors [15]. Long-term data on safety of MEK162 are
still awaited however.
In conclusion, we report a case of NCM with pro-
gressive symptomatic leptomeningeal melanocytosis
harboring a somatic NRASQ61K mutation that was
experimentally treated with MEK162. We observed adecrease in proliferation as well as a decrease in pERK
expression in the post-treatment melanocytosis sam-
ples as compared to a pre-treatment sample, suggest-
ing an effect of MEK inhibiting therapy. However,
further studies are needed to determine whether MEK
inhibitors can effectively target NRAS-mutated NCM.
This is important considering the often fatal course of
symptomatic NCM and the limited treatment options
that are available for this disorder.
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